Heart drug safety checked in small indian patient group
NCT ID NCT06086353
Summary
This study monitored the safety of the drug Tafamidis (VyndaMx®) in six Indian patients diagnosed with a serious heart condition called ATTR-CM. The condition is caused by a protein clumping in the heart, making it harder to pump. Researchers tracked any side effects patients experienced over six months after starting the medication to understand its safety profile.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AIG Hospital
Hyderabad, 500032, India
-
Max Super Speciality Hospital
New Delhi, 110017, India
-
Sri Jayadeva Institute of Cardiovascular Sciences and Research
Bangalore, Karnataka, 560069, India
Conditions
Explore the condition pages connected to this study.